FIG. 4.

Development of body temperature, clinical scores, and serum neutralizing antibody titers of infected animals. (A) Rectal body temperature was measured 0 to 6 days postchallenge in each group. (B) The clinical score was evaluated according to clinical symptoms (see Materials and Methods for a definition). A total of six groups, with five animals per group (except group 6, with only four animals) were used. Group 1 was not vaccinated, group 2 was vaccinated with a DOE-FMD vaccine 2 days before challenge, group 3 was vaccinated with DOE-FMD and CpG in Emulsigen 2 days before challenge, group 4 was vaccinated with DOE-FMD 7 days before challenge, group 5 was vaccinated with DOE-FMD and CpG in Emulsigen 7 days before challenge, and group 6 was vaccinated 21 days before challenge with a conventional DOE type O₁ Manisa vaccine. Each animal among a group is depicted by an open symbol (circle, square, triangle, diamond, or cross). The line represents the median value in each group. (C) Based on nonspecific virus neutralization with sera from naive animals, the cutoff was defined at a titer of 10 TCID₅₀/ml. A total of six groups, with five animals per group (except group 6, with only four animals) were used. Group 1 was not vaccinated, group 2 was vaccinated with a DOE-FMD vaccine 2 days before challenge, group 3 was vaccinated with a DOE-FMD and CpG in Emulsigen 2 days before challenge, group 4 was vaccinated with DOE-FMD 7 days before challenge, group 5 was vaccinated with DOE-FMD and CpG in Emulsigen 7 days before challenge, and group 6 was vaccinated 21 days before challenge with a conventional DOE type O₁ Manisa vaccine. Each animal among a group is depicted by an open symbol (circle, square, triangle, diamond, or cross).